Controversial firm RNL Bio quick to welcome Korean stem cell bill
This article was originally published in Scrip
Political moves in South Korea to revise rules governing the use of autologous adult stem cells have found one high profile, if controversial, proponent in Dr Ra Jeong-Chan of the domestic stem cell venture RNL Bio.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.